Rahul Banerjee, MD

Rahul Banerjee, MD, discusses the rationale for potential therapeutic strategies to address T-cell exhaustion following CAR T-cell therapy in multiple myeloma.

Rahul Banerjee, MD, discusses a potential mechanism for checkpoint inhibition following CAR T-cell therapy in patients with multiple myeloma.

Rahul Banerjee, MD, FACP, physician-researcher at Fred Hutch Cancer Center in Seattle, WA, discusses the potential links between CAR T-cell therapy and secondary T-cell malignancies.

Rahul Banerjee, MD, discusses new frontiers in the treatment of multiple myeloma with CAR T-cell therapy.